Graves’ Disease Clinical Trials and Treatments

Graves' disease is an organ-specific autoimmune disorder caused by thyroid-stimulating antibodies (TSAb) that bind to and activate the TSH receptor on thyroid follicular cells, causing unregulated thyroid hormone production. The resulting hyperthyroidism affects virtually every organ system. Cardiovascular effects include tachycardia, atrial fibrillation, and high-output heart failure.

The most common symptoms of Graves’ Disease include Rapid or irregular heartbeat (palpitations), Unexplained weight loss despite increased appetite, Tremors in hands and fingers, Heat intolerance and increased sweating, Bulging eyes (exophthalmos) or eye irritation, among others. Affects about 1 in 200 people; most common in women ages 30-50. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Graves’ Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Graves' disease treatment is entering a new era focused on addressing the root cause rather than destroying the thyroid. Clinical trials are testing fundamentally different approaches, including Biohaven's BHV-1300, an IgG degrader that lowered the disease-causing TSH receptor antibodies by about 80% by week 12 in its Phase 1b study, with free T4 back to normal after a median of 3 weeks, and entered a Phase 3 trial (NCT07661056) in about 300 adults with Graves' hyperthyroidism in June 2026.

Yes. As of October 21, 2026, 2 FDA-approved medicines have a current label that names Graves’ Disease: Methimazole; and Propylthiouracil. Corticosteroids and immune globulins count once each.

The exact cause of Graves’ Disease is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoimmune; HLA and other immune-gene variants each add only a small amount of risk, and no diagnostic gene test exists. Affects about 1 in 200 people; most common in women ages 30-50. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Graves’ Disease. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoimmune; HLA and other immune-gene variants each add only a small amount of risk, and no diagnostic gene test exists.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Graves’ Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Graves’ Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.